Join Oncolytics for a key opinion leader (KOL) webinar to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers.

The event will feature insights from leading experts:

• Dirk Arnold, M.D., Ph.D. – Asklepios Tumorzentrum Hamburg
• Alexander Eggermont, M.D., Ph.D. – University Medical Center Utrecht
• Sanjay Goel, M.D., M.S., FASCO – Rutgers Cancer Institute of New Jersey
• Devalingam Mahalingam, M.D., Ph.D. – Northwestern University

The event will review the existing pelareorep pancreatic cancer data, including the GOBLET trial, and pelareorep’s future potential in the evolving pancreatic and gastrointestinal cancer treatment landscape. Pelareorep is a first-in-class, nonpathogenic, oncolytic virus that can be delivered intravenously and works by generating, recruiting, and training immune cells to recognize and kill cancer while remodeling the tumor microenvironment to enable immune cell access.

A live question and answer session will follow a formal presentation and roundtable discussion with the KOLs.